DelveInsight’s “Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2032” report provides an in-depth understanding of Generalized Anxiety Disorder, historical and forecast epidemiology, and Generalized Anxiety Disorder market trends to United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Generalized Anxiety Disorder market is expected to rise owing to the growing prevalence and awareness of the disease over the forecast period. Furthermore, the launch of various multi-stage generalized anxiety disorder pipeline products will significantly revolutionize the generalized anxiety disorder market dynamics.
Overview of Generalized Anxiety Disorder
Generalized anxiety disorder (GAD) is recognized as the most common anxiety disorder in primary care, resulting in a significant degree of comorbidity, impairment, and disability. GAD is characterized by a chronic, persistent pattern of worry, anxiety symptoms, and tension that progresses upwards and downwards, often without complete remission.
DSM-V criteria for generalized anxiety disorder include features such as feeling agitated, excited or nervous, easily fatigued, difficulty concentrating or having a vacant mind, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness.
Some of the key facts of the Generalized Anxiety Disorders Market report
- Generalized Anxiety Disorders Market Size is Expected to Grow with Significant CAGR over the Study Period (2019-2032)
- Anxiety is the most common mental disorder in the United States, affecting approximately 40 million adults
- The majority of anxious adults have a mild impairment (43.5%), 33.7% have a moderate impairment and 22.8% have a severe impairment
- Anxiety disorders are more common in women than in men. Anxiety affects 23% of adult women and
- 14% of adult men
- Generalized anxiety disorder is often unrecognized or misdiagnosed as a physical condition due to the range of clinical presentations, including somatic symptoms, and the frequent occurrence of comorbid conditions.
- Key GAD companies: Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories, Sage Therapeutics, Biohaven Pharmaceuticals, Fabre-Kramer Pharmaceuticals and others
- Key therapies for generalized anxiety disorder: vortioxetine, duloxetine, troriluzole, vilazodone, quetiapine fumarate and others
- Gender-Based Epidemiology of Generalized Anxiety Disorder analyzed that Generalized Anxiety Disorder (GAD) is more prevalent in females than in males
Download Free Sample Report of Generalized Anxiety Disorders Market
Key Benefits of the Generalized Anxiety Disorders Market Report:
- The Generalized Anxiety Disorders Market report covers a descriptive overview and comprehensive overview of the Generalized Anxiety Disorders and Generalized Anxiety Disorders epidemiology market in 7MM (US, EU5 (Germany, Spain, France, Italy, UK) and Japan.)
- The Generalized Anxiety Disorders Market report provides information on current and emerging therapies.
- The Generalized Anxiety Disorders Market report provides historical and forecasted global market covering the spread of drugs in 7MM.
- The Generalized Anxiety Disorders Market report offers an advantage which will help in developing business strategies by understanding the trends shaping and driving the Generalized Anxiety Disorders market.
Learn More About Therapies Aimed to Capture Major Generalized Anxiety Disorder Market Share @ Generalized Anxiety Disorder Market Forecast
Epidemiological segmentation of generalized anxiety disorders:
The Generalized Anxiety Disorder Market report offers epidemiological analysis for the study period 2019-2032 in 7MM segmented into:
- Total prevalence of generalized anxiety disorder
- Prevalent cases of generalized anxiety disorder by severity
- Gender prevalence of generalized anxiety disorder
- Diagnosed cases of episodic and chronic generalized anxiety disorder
Generalized Anxiety Disorders Market
The generalized anxiety disorder market dynamics are expected to change in the coming years owing to the expected launch of emerging therapies such as EXXUA, SAGE-217 and others during the forecast period 2019-2032.
“Currently, only a few companies are actively involved in the development of therapies for generalized anxiety disorder, however, given the disease burden associated with generalized anxiety disorder, there is an urgent need for new therapies to meet patient needs. ”
Download the report to understand what factors drive the epidemiological trends of Generalized Anxiety Disorder @ Epidemiological Insights of Generalized Anxiety Disorder
Highlights of the Generalized Anxiety Disorders Market
- Significant advances have been made in understanding disease pathology, diagnosis, and treatment effects in generalized anxiety disorder (GAD)
- Neonatal screening for generalized anxiety disorder (GAD) has been implemented in several countries, allowing the early detection of individuals carrying Fabry mutations
- Many therapies are being studied in various phases of clinical trials. These include pegylated forms of α-GAL, gene therapy and substrate reduction therapy
Generalized Anxiety Disorder Therapies and Key Companies
- Vortioxetine: Takeda
- Duloxetine: Astra Zeneca
- Troriluzole: Eli Lilly and company
- Vilazodone: Forest laboratories
- Quetiapine fumarate: Sage Therapeutics and others
Scope of the Generalized Anxiety Disorders Market Report
- Study period: 2019-2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key GAD companies: Takeda, AstraZeneca, Eli Lilly and Company, Forest Laboratories, Sage Therapeutics, Biohaven Pharmaceuticals, Fabre-Kramer Pharmaceuticals and others
- Key therapies for generalized anxiety disorder: vortioxetine, duloxetine, troriluzole, vilazodone, quetiapine fumarate and others
- Therapeutic assessment: currently marketed therapies for generalized anxiety disorder and emerging therapies for generalized anxiety disorder
- Generalized Anxiety Disorder Market Dynamics: Generalized Anxiety Disorder Market Drivers and Barriers
- Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG matrix, market entry strategies
- Unmet Needs, KOL Views, Analyst Views, Generalized Anxiety Disorder Market Access and Reimbursement
Generalized Anxiety Disorder Market Opportunities
- Development of a potential biomarker that can track and predict the severity and potential course of disease and the effectiveness of any therapeutic intervention
- The relative lack of efficacy of enzyme replacement therapy, partly due to antibody formation, can be alleviated by combining new oral therapy approaches
- Due to the poor quality of life of patients with generalized anxiety disorder (GAD), there is a significant willingness of patients towards expensive therapies
Unmet Needs of the Generalized Anxiety Disorders Market
- Challenges in diagnostics
- Development of new therapies for generalized anxiety
- The limits of gene therapy
- Misunderstanding of disease
- Clinical biomarkers
Contents
1. Introduction to Generalized Anxiety Disorders Market Report
2. Executive Summary for Generalized Anxiety Disorder
3. SWOT Analysis of Generalized Anxiety Disorder
4. Share of Patients with Generalized Anxiety Disorder (%) Overview at a Glance
5. Generalized Anxiety Disorder Market Overview at a Glance
6. History and Overview of Generalized Anxiety Disorder Illness
7. Epidemiology of generalized anxiety disorder and patient population
8. Country-Specific Generalized Anxiety Disorder Patient Population
9. Generalized Anxiety Disorder Current Treatment and Medical Practices
10. Unmet Needs of Generalized Anxiety Disorder
11. Emerging Therapies of Generalized Anxiety Disorder
12. Generalized Anxiety Disorders Market Outlook
13. Generalized Anxiety Disorders Market Analysis by Countries (2019-2032)
14. Access to the Generalized Anxiety Disorders Market and Reimbursement of Therapies
15. Generalized Anxiety Disorders Market Drivers
16. Generalized Anxiety Disorder Market Barriers
17. Generalized Anxiety Disorder Appendix
18. Generalized Anxiety Disorders Report Methodology
19. DelveInsight Abilities
20. Disclaimer
21. About DelveInsight
To learn more about treating Generalized Anxiety Disorder, visit @ Generalized Anxiety Disorder Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Gaurav Bora
E-mail: Send an email
Call: 9193216187
Address:304 S. Jones Boulevard #2432
Town: Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/